Alvotech (ALVO) Other Non-Current Assets (2020 - 2026)
Alvotech's (ALVO) quarterly Other Non-Current Assets came in at $15.0 million in Q1 2026, up 313.75% YoY from $3.6 million in Q1 2025, and up 74.36% on a QoQ basis from $8.6 million in Q4 2025.
Alvotech (ALVO) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has 7 years of Other Non-Current Assets data on file, last reported at $15.0 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 313.75% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (up 313.75% YoY) and the FY2025 annual result came in at $8.6 million, down 62.23% from the prior year.
- Other Non-Current Assets advanced to $15.0 million in Q1 2026, from $8.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $26.1 million in Q4 2023 to a low of $3.6 million in Q1 2025.
- A 5-year average of $17.5 million and a median of $23.9 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets slumped 85.54% — and 2026, when it jumped 313.75%.
- Tracing ALVO's Other Non-Current Assets over 5 years: stood at $25.2 million in 2022, then gained by 3.75% to $26.1 million in 2023, then slipped by 13.1% to $22.7 million in 2024, then slumped by 62.23% to $8.6 million in 2025, then surged by 74.36% to $15.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $15.0 million (Q1 2026), $8.6 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | 14.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.96 Mn |
| Dec 31, 2025 | 8.58 Mn |
| Sep 30, 2025 | 4.73 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 3.62 Mn |
| Dec 31, 2024 | 22.71 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 25.00 Mn |
| Mar 31, 2024 | 25.00 Mn |
| Dec 31, 2023 | 26.13 Mn |
| Jun 30, 2023 | 25.19 Mn |
| Mar 31, 2023 | 25.19 Mn |
| Dec 31, 2022 | 25.19 Mn |
| Jun 30, 2022 | 25.00 Mn |
| Dec 31, 2021 | 10.09 Mn |
| Dec 31, 2020 | 10.09 Mn |